Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Mutations in EPHB4 cause human venous valve aplasia
Oliver Lyons, … , Prakash Saha, Alberto Smith
Oliver Lyons, … , Prakash Saha, Alberto Smith
Published August 17, 2021
Citation Information: JCI Insight. 2021;6(18):e140952. https://doi.org/10.1172/jci.insight.140952.
View: Text | PDF
Research Article Angiogenesis Development

Mutations in EPHB4 cause human venous valve aplasia

  • Text
  • PDF
Abstract

Venous valve (VV) failure causes chronic venous insufficiency, but the molecular regulation of valve development is poorly understood. A primary lymphatic anomaly, caused by mutations in the receptor tyrosine kinase EPHB4, was recently described, with these patients also presenting with venous insufficiency. Whether the venous anomalies are the result of an effect on VVs is not known. VV formation requires complex “organization” of valve-forming endothelial cells, including their reorientation perpendicular to the direction of blood flow. Using quantitative ultrasound, we identified substantial VV aplasia and deep venous reflux in patients with mutations in EPHB4. We used a GFP reporter in mice to study expression of its ligand, ephrinB2, and analyzed developmental phenotypes after conditional deletion of floxed Ephb4 and Efnb2 alleles. EphB4 and ephrinB2 expression patterns were dynamically regulated around organizing valve-forming cells. Efnb2 deletion disrupted the normal endothelial expression patterns of the gap junction proteins connexin37 and connexin43 (both required for normal valve development) around reorientating valve-forming cells and produced deficient valve-forming cell elongation, reorientation, polarity, and proliferation. Ephb4 was also required for valve-forming cell organization and subsequent growth of the valve leaflets. These results uncover a potentially novel cause of primary human VV aplasia.

Authors

Oliver Lyons, James Walker, Christopher Seet, Mohammed Ikram, Adam Kuchta, Andrew Arnold, Magda Hernández-Vásquez, Maike Frye, Gema Vizcay-Barrena, Roland A. Fleck, Ashish S. Patel, Soundrie Padayachee, Peter Mortimer, Steve Jeffery, Siren Berland, Sahar Mansour, Pia Ostergaard, Taija Makinen, Bijan Modarai, Prakash Saha, Alberto Smith

×

Figure 3

EphB4 is expressed on E18 and P0 and is required for normal VFC organization and leaflet development to P6.

Options: View larger image (or click on image) Download as PowerPoint
EphB4 is expressed on E18 and P0 and is required for normal VFC organiza...
(A and B) Homozygous deletion of Ephb4 on E15 (analyzed on P0) resulted in disrupted organization of VFCs, similar to deletion of Efnb2, albeit some VVs appeared to develop normally. The number of VVs analyzed for each condition is indicated above each bar in the chart. *P = 0.008, Fisher’s exact test. Scale bars: 20 μm. (C) EphB4 was localized in WT P6 VVs and surrounding vein. The leaflet of a stage 3 VV is indicated by arrowheads. L = valve lumen and C = the single commissure. In adult VVs, longitudinal sections were prepared, and EphB4 (dark blue stain) was most strongly localized to the luminal surface of VV leaflets (black arrowheads) and leaflet free edge (enlarged in inset). The counterstain is Nuclear Fast Red. Arrows indicate the orientation of the adult histological section only (all confocal images are oriented as shown in Figure 2). (D and E) Induction of homozygous Ephb4 deletion on P0 with tamoxifen (analysis on P6) resulted in entirely absent VV leaflets and failure to remodel the surrounding SMCs (arrowheads in upper panel) on P6. Only a few Prox1hi/Foxc2hi cells remained (arrowhead in lower panel). The asterisk indicates a downstream tributary valve. (E) Bar chart shows the proportion of VVs identified at each stage, with stage and color indicated in adjacent key, on P6 for the indicated genotypes. The number of VVs analyzed for each condition is given above each bar. ****P < 0.00005, χ2 vs. control, n = 13 control VVs vs. 10 Ephb4 deleted. Scale bars in A, C, and D: 20 μm. VFCs, valve-forming cells; VVs, venous valves; E18, embryonic day 18; P0, postnatal day 0; Tam; tamoxifen; SMA, smooth muscle α-actin; SMC, smooth muscle cell.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts